Search for content, post, videos

Evaluation of Acarix’s CADScor System completed


Acarix announces that two Swedish hospitals – Kristianstad and Sunderbyn – have evaluated the CADScor System for rule-out of Coronary Artery Disease.

The evaluation compares favorably against existing methods and offers the possibility of avoiding expensive invasive methods, reports the company. Kristianstad will now integrate the CADScor System in daily clinical practice while Sunderbyn will move to a second evaluation phase with the aim of adoption by year end.

Kristianstad Central Hospital

Kristianstad Central Hospital validated the CADScor System by comparing it to a well-established reference method, Myocardial Perfusion Scan. The clinical outcome was in line with the outcomes in previously published studies for the handheld device. The clinic is planning to start using the CADScor System as a complementary assessment in selected patients from the fourth quarter 2018.

Sunderbyn Hospital

Sunderbyn Hospital in Luleå has during the second quarter finalized the first phase of evaluating the CADScor System. The results are in line with the reported sensitivity, specificity and negative predictive value for ruling out Coronary Artery Disease. Therefore, the clinic will, during the fall, continue with the second phase of evaluation which is planned to be finalized during the fourth quarter.

“The outcome from the first phase of evaluation is very promising. It showed that the results from previous clinical trials can be trusted in clinical settings. Now we are moving on to the second phase to finalize our local evaluation. We are looking forward to the results, and to implement the CADScor System in our daily, clinical practice if also the second phase of evaluation confirms previous published clinical data,” says Kambiz Shahgaldi, PhD, Associate Professor at the Department of Clinical Physiology in Luleå. “We are delighted with the results of the evaluations from these highly regarded Swedish hospitals and expect to achieve significant market penetration by the end of the year,” says Acarix Chief Commercial Officer Per Persson.

The CADScor System

The CADScor System provides a non-invasive ultra-sensitive detection of turbulent arterial flow and myocardial movement in a portable device to provide a patient-specific score to assess the risk for Coronary Artery Disease (CAD) in less than 8 minutes. This provides physicians with a rapid first line tool for early assessment before moving on to more expensive invasive methods.